Data in this report delineate a pathway, which regulates alternative RNA splicing in lung adenocarcinomas, and they show that the influence of the pathway on the biology of tumors harboring EGFR mutations is more robust, than its influence on the biology of tumors harboring KRAS mutations. Here, KRAS is linked to lung adenocarcinoma.